Positron emission tomography in oncology

W. R. Hendee, G. M. Bohigian, E. H. Estes, I. R. Friedlander, W. R. Kennedy, J. H. Moxley, P. J. Numann, P. S. Salva, W. C. Scott, J. H. Skom, R. M. Steinhilber, J. P. Strong, H. H. Wagner, W. T. McGivney, J. S. Favler, E. J. Hoffman, S. M. Larson, H. R. Schelbert, M. Schwaiger

Research output: Contribution to journalReview articlepeer-review

Abstract

This report describes the current and potential uses of positron emission tomography in clinical medicine and research related to oncology. Assessment will be possible of metabolism and physiology of tumors and their effects on adjacent tissues. Specific probes are likely to be developed for target sites on tumors, including monoclonal antibodies and specific growth factors that recognize tumors. To date, most oncological applications of positron emission tomography tracers have been qualitative; in future, quantitative metabolic measurements should aid in the evaluation of tumor biology and response to treatment.

Original languageEnglish (US)
Pages (from-to)2126-2131
Number of pages6
JournalJournal of the American Medical Association
Volume259
Issue number14
DOIs
StatePublished - Apr 29 1988

Fingerprint Dive into the research topics of 'Positron emission tomography in oncology'. Together they form a unique fingerprint.

Cite this